The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.
After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.
The London-based firm said it will use the funds to advance its gene therapy pipeline, including its lead program in IgA nephropathy.